BACKGROUND: Interleukin-2(IL-2), also called T-cell growth factor and primarily produced by antigen-activated T cells, is a kind of lymphoid factor with immunoregulatory effect which can promote T-cell-dependent immune responses. IL-2 was first used as a therapeutic approach to boost immune responses in patients with invasive cancer or advanced HIV disease. OBJECTIVES: The purpose of the review is to refer the mechanism of autoimmune disease caused by IL-2 deletion and the application of IL-2 in curing autoimmune disease. STATE OF THE ART: IL-2 signal plays a key role in promoting the development, homeostasis and the function of the regulatory T cells. The deletion of IL-2 in vivo causes T cell-mediated autoimmune diseases. Now it is being considered as a kind of medicine inhibiting immune responses. PERSPECTIVES: Further studies with controlled clinical trials will be needed to prove the potential of IL-2 as a therapeutic strategy for autoimmune diseases. CONCLUSIONS: The decreased production of IL-2 in patients with autoimmune disease leads to immune defects, such as decreased production of Treg cells, decreased AICD and cytotoxicity. Combination therapy based on IL-2 may prove to be beneficial in curing the immunological disorders.
BACKGROUND:Interleukin-2(IL-2), also called T-cell growth factor and primarily produced by antigen-activated T cells, is a kind of lymphoid factor with immunoregulatory effect which can promote T-cell-dependent immune responses. IL-2 was first used as a therapeutic approach to boost immune responses in patients with invasive cancer or advanced HIV disease. OBJECTIVES: The purpose of the review is to refer the mechanism of autoimmune disease caused by IL-2 deletion and the application of IL-2 in curing autoimmune disease. STATE OF THE ART: IL-2 signal plays a key role in promoting the development, homeostasis and the function of the regulatory T cells. The deletion of IL-2 in vivo causes T cell-mediated autoimmune diseases. Now it is being considered as a kind of medicine inhibiting immune responses. PERSPECTIVES: Further studies with controlled clinical trials will be needed to prove the potential of IL-2 as a therapeutic strategy for autoimmune diseases. CONCLUSIONS: The decreased production of IL-2 in patients with autoimmune disease leads to immune defects, such as decreased production of Treg cells, decreased AICD and cytotoxicity. Combination therapy based on IL-2 may prove to be beneficial in curing the immunological disorders.
Authors: Anna Galstyan; Janet L Markman; Ekaterina S Shatalova; Antonella Chiechi; Alan J Korman; Rameshwar Patil; Dmytro Klymyshyn; Warren G Tourtellotte; Liron L Israel; Oliver Braubach; Vladimir A Ljubimov; Leila A Mashouf; Arshia Ramesh; Zachary B Grodzinski; Manuel L Penichet; Keith L Black; Eggehard Holler; Tao Sun; Hui Ding; Alexander V Ljubimov; Julia Y Ljubimova Journal: Nat Commun Date: 2019-08-28 Impact factor: 14.919
Authors: Gamal Badr; Leila H Sayed; Hossam El-Din M Omar; Sary Khaleel Abd Elghaffar; Medhat M Menshawy Journal: Environ Sci Pollut Res Int Date: 2022-05-13 Impact factor: 5.190